AlphAIAlphAI — Financial news for AI agents
investing.comSEP 111 min read$JNJ

Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports

Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, for around $20 billion. The unit, which generated $9.3 billion in sales in 2025, is planned to be separated into a standalone company. Bloomberg News cited sources for the report, but Reuters could not verify it. J&J and Apollo Global Management did not comment.

Original reporting
investing.com
Published Sep 11, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$JNJ
Neutral
high confidence
Mentioned
$JNJ · $APO
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$JNJNeutralMed
01

Why it matters

Potential deal could reshape the medical‑device landscape and affect related stocks.

02

Market read

M&A talks introduce material news for both JNJ and APO, with possible price moves.

03

What to watch

Regulatory approval risk and integration challenges for JNJ's unit.

Relevance 8/10Novelty 8/10Timing: today

Background

Apollo Global Management is exploring acquisition of JNJ's DePuy Synthes orthopedics unit, valued near $20 billion.

Company-level read

Ticker impact

$JNJNeutralHigh confidence
Context

Apollo Global Management is in talks to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, in a deal valued near $20 billion.

Expected impact

JNJ may face short-term pressure; APO could see modest upside on acquisition rumors.

Evidence & confidence

Deal size and strategic fit are material; market will price in acquisition risk and upside.

$APONeutralHigh confidence
Context

Apollo Global Management is reported to be negotiating a $20 billion purchase of JNJ's orthopedics business.

Expected impact

APO could experience a modest rally as investors price in possible transaction.

Evidence & confidence

Large‑scale M&A news typically moves the acquirer’s stock, especially for a private‑equity firm.

Market effects

Sector

Consolidation in medical devices could pressure other orthopedics peers.

Regional

U.S. healthcare sector may see valuation adjustments.

Global

Large M&A could influence global private‑equity activity.

Counterpoint

What could challenge this read

Deal may fall apart, leaving both stocks unchanged.

Key entities

  • Company
    Johnson & Johnson

    Owner of DePuy Synthes orthopedics unit.

  • Company
    Apollo Global Management

    Private‑equity firm pursuing the acquisition.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 22
$JNJMedAI 8/10

J&J Reports New Data on Atrial Fibrillation Devices

Johnson & Johnson presented new clinical data for its atrial fibrillation devices at the Asia Pacific Heart Rhythm Society 2026 meeting. The Varipure device showed 100% acute procedural success in 225 patients, while 82.5% of 136 Omnypulse patients had no recurrence after 12 months.

ocbj.com2 min
OCT 22
$JNJMedAI 8/10

Why is Johnson & Johnson stock rallying today?

Johnson & Johnson (JNJ) stock rose 3.0% after presenting positive clinical data for its pulsed field ablation technology at a conference. The VARIPURE and Omny-IRE studies showed high success rates and low adverse events. Analysts raised price targets, with Wells Fargo setting a new target of $287. Despite a broader market decline, JNJ's stock gained due to its defensive appeal and strong pharmaceutical segment growth.

investing.com2 min
OCT 22
$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

massdevice.com2 min
OCT 22
$JNJMedAI 8/10

Johnson & Johnson Presents Breakthrough Atrial Fibrillation Stud

Johnson & Johnson (JNJ) presented positive clinical trial results for atrial fibrillation treatments at a conference. The VARIPURE study showed 100% procedural success, while Omny-IRE achieved 82.5% success in preventing arrhythmia recurrence. JNJ has a 2.06% dividend yield, 70% payout ratio, and 4.9% dividend growth over three years. The stock trades 32.5% above its GF Value™, with insiders selling $150.7M in shares over the past year.

gurufocus.com3 min
OCT 22
$JNJMedAI 8/10

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026

Johnson & Johnson (JNJ) presented data from VARIPURE and Omny-IRE studies at APHRS 2026. VARIPULSE Pro Platform showed 100% acute procedural success, 0.4% adverse event rate, and 17.9-minute mean ablation time. OMNYPULSE Platform had 82.5% freedom from arrhythmia recurrence at 12 months. Both studies support JNJ's atrial fibrillation treatment technologies.

finanznachrichten.de3 min
OCT 22
$JNJMedAI 8/10

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platfor

Johnson & Johnson (JNJ) presented data from VARIPURE and Omny-IRE studies at APHRS 2026. VARIPULSE Pro showed 100% acute procedural success in 225 patients, with a 0.4% adverse event rate. OMNYPULSE Platform had 82.5% freedom from AF recurrence at 12 months. CARTO 3 System data showed lower long-term AF-related acute-care utilization compared to EnSite.

gurufocus.com2 min